MAPT and Alzheimer disease: In the transgenic 3×Tg-AD mouse model, Green and collaborators demonstrated that nicotinamide treatment restored cognitive deficits through a reduction of phosphorylated species of tau (Thr231-phosphotau) (Green et al., 2008).